Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lysine-3,4-methylenedioxyamphetamine
- Development stage
- Phase 1
- Lead developer
- MiHKAL
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lysine-3,4-methylenedioxyamphetamine (Lys-MDA) is a substituted amphetamine derivative with empathogenic effects. It acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA is being investigated as a potential treatment for treatment-resistant depression and post-traumatic stress disorder.
- Other names
- Lys-MDAN-(L-lysinamidyl)-3,4-methylenedioxyamphetamine
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on lysine-3,4-methylenedioxyamphetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lysine-3,4-methylenedioxyamphetamine.